Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.990
-0.100 (-1.96%)
Aug 6, 2026, 11:19 AM EDT - Market open

Vanda Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
215.72216.11198.77192.64254.38268.68
Revenue Growth
6.02%8.72%3.18%-24.27%-5.32%8.27%
Gross Profit
202.22203.06187.46177.84230.1243.05
Operating Income
-185.67-151.17-40.66-13.956.3342.17
Net Income
-274.85-220.47-18.92.516.2833.15
Earnings Per Share
-4.63-3.74-0.330.040.110.58
EPS Growth
----63.64%-81.03%38.09%

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
170.03263.85374.64388.26466.86432.81
Total Debt
18.27.078.097.018.8110.06
Net Cash (Debt)
151.83256.78366.55381.26458.05422.76
Net Cash Growth
-52.34%-29.95%-3.86%-16.76%8.35%18.67%
Net Cash Per Share
2.554.366.306.628.047.43

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-142.33-109.44-15.7612.831.9864.21
Capital Expenditures
-0.67-1-0.49-0.38-0.68-0.55
Free Cash Flow
-143.01-110.44-16.2512.4231.3163.66
Free Cash Flow Growth
----60.33%-50.83%27.38%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
93.74%93.96%94.31%92.32%90.45%90.46%
Operating Margin
-86.07%-69.95%-20.46%-7.24%2.49%15.69%
Pretax Margin
-82.14%-64.16%-11.53%3.29%4.44%15.77%
Profit Margin
-127.41%-102.02%-9.51%1.30%2.47%12.34%
FCF Margin
-66.29%-51.10%-8.17%6.45%12.31%23.69%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
---105.5067.1827.05
Forward PE
-23.7423.7423.7421.7421.94
P/FCF Ratio
---19.5513.4013.78
PS Ratio
1.422.411.411.261.653.26